Drug Schedules under the Drugs & Cosmetics Act

Statutory architecture & scope

• The parent statute — the Drugs Act, 1940 controls the manufacture, sale and distribution of drugs in India; a 1962 amendment added cosmetics, renaming it the Drugs and Cosmetics (D&C) Act. It now also covers Ayurvedic, Siddha, Unani and Homoeopathic drugs.
• Two-tier legal structure — the Act, 1940 is parent legislation passed by Parliament; the Rules, 1945 are delegated legislation, amendable by gazette notification (G.S.R.) without re-legislating. Exam consequence: only the First Schedule (ASU formulary books) and Second Schedule (standards of quality) belong to the Act; the whole A → Y run belongs to the Rules — though there is no Schedule W, Schedule I was omitted (1982), and E exists only as E(1).
• What a "Schedule" is — an annexure to the Rules grouping drugs (or forms, fees, standards, premises, exempted categories) that share a common regulatory treatment, and prescribing the labelling, prescription, sale, storage, record-keeping, manufacturing or testing duties attaching to that group.
• Every schedule works only through a Rule — each heading carries a "(See Rule N)" cross-reference and the substantive obligation lives in that Rule — learning the pairings is the highest-yield route to this topic.
  • G, H, H1, X → Rules 65 and 97 (sale + labelling); X additionally → Rules 23, 61, 75, 105A · C, C(1) → Rules 23, 61, 76 · P → Rule 96 · P1 → Rules 105, 109 · J → Rule 106 · K → Rule 123 · M → Rules 71, 74, 76, 78 · N → Rule 64(1) · Y → Rules 122A–122E.
• Regulators & enforcement — CDSCO, headed by the DCGI, is the central licensing authority (new-drug approval, trial permission, imports, Schedule C/C(1) and X oversight); State Drug Control Authorities license manufacture and sale and appoint Drugs Inspectors. Breach of a Rule-65 condition grounds licence suspension or cancellation under Rule 66. Note this is the Indian D&C schedule system — not US Controlled Substances Act scheduling, and not the NDPS Act lists.